1 / 17

Coverage and Payment for Biotechnology and Medical Devices Academy Health June 4, 2007 Thomas Weisman, MD, MBA Ohio Medi

Coverage and Payment for Biotechnology and Medical Devices Academy Health June 4, 2007 Thomas Weisman, MD, MBA Ohio Medical Director Anthem Blue Cross and Blue Shield. Agenda P & T Process Cost of Care Committees Value Chain Transparency Examples Herceptin

ova
Download Presentation

Coverage and Payment for Biotechnology and Medical Devices Academy Health June 4, 2007 Thomas Weisman, MD, MBA Ohio Medi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Coverage and Payment for Biotechnology and Medical Devices Academy Health June 4, 2007 Thomas Weisman, MD, MBA Ohio Medical Director Anthem Blue Cross and Blue Shield

  2. Agenda • P & T Process • Cost of Care Committees • Value Chain • Transparency • Examples • Herceptin • Specialty Pharmacy

  3. P & T Process • Clinical Review Committee (CRC) • Majority external representation • Assessment of efficacy only • Superior • Equivalent • Inferior

  4. P & T Process • Value Added Committee (VAC) • Internal representatives • Cannot disadvantage superior medication • Within restrictions, business needs rule

  5. Cost of Care Committees • Provider Relations • Medical Directors • Actuaries • Support areas • PBM • Behavioral Health • Operations

  6. Cost of Care Committees • State level (OH) • Central Zone (OH, IN, KY, MO, WI) • Enterprise

  7. Value Chain • Deconstruct and examine each step/activity • Is this an activity a customer would pay extra for? • Internal activities • Device/Pharmaceutical

  8. Transparency • Cost and (limited) quality information • 38 elective services • Cost • Event or “shoebox” methodology • Results presented in “bands” • Can see impact on member responsibility • Quality • Volume of cases • Access to Subimo information

  9. Transparency • Consumer Directed Health Plans (CDHP) • Increasing consumer cost sharing • Increasing consumer engagement • Increasing market forces • Increasing consumer focus on value chain

  10. Herceptin • Monoclonal antibody • Useful in HER2 positive breast cancer • Useless in HER2 negative breast cancer • Cardiotoxic • Expensive • Weekly infusions, either alone or in combination chemo regimens

  11. Herceptin • J9355 Summary by Financial Arrangement (OH, IN, KY, MO, WI) • Total 23,618,980 • After rem Medicare claims 18,668,905 • After rem NASCO ASO 8,024,165 • Tot allowed amt for Fully Ins (after rem other ASO) 5,609,691

  12. Herceptin United Health Care Pilot (anecdotal information) demonstrated that 11-12% of women receiving Herceptin did not have documentation of positive HER2 gene test

  13. Herceptin Proposal • Activate CG-DRUG-02 as of 7/30/2007—no grandfathering • Require documentation of positive HER2 and attestation of normal cardiac function • Letter to all oncologists • Separate letter to oncologists with members on Herceptin • Rapid update

  14. Herceptin Proposal • Create Provider Tool and Desktop • Training for MD’s and for RN’s in Pre-D, Med Review and Precert • Provider Relations, Med Review, Pre-D and Specialty Rx sign-on • Track PMPM (absolute and trend) compared to states not managing Herceptin • Track denial rates

  15. Specialty Pharmacy • Pilot in California, Colorado and Nevada • 84 (soon 87) medications require guideline-based authorization for payment • Some medications (by volume, 5% of above) will require purchase from PrecisionRx Specialty Services including: • Hemophilia factors • TNF inhibitors ( but not Remicade) • Synagis • Somatotropins and Gonadotropins • Hyaluronic acid derivatives • Interferons • Enzyme replacement products

  16. Conclusion • Health plan decision-making will be driven by concerns for: • Affordability • Patient safety • Value • Transparency and Consumer engagement will reinforce above trends • Initial efforts focused on newer agents and “low hanging fruit”

  17. Trademark Information • Anthem Blue Cross and Blue Shield is the trade name of: In Colorado: Rocky Mountain Hospital and Medical Service, Inc. In Connecticut: Anthem Health Plans, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In most of Missouri: RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. In Ohio: Community Insurance Company. In most of Virginia: Anthem Health Plans of Virginia, Inc. In Wisconsin: Blue Cross Blue Shield of Wisconsin ("BCBSWi") underwrites or administers the PPO and indemnity policies; Compcare Health Services Insurance Corporation ("Compcare") underwrites or administers the HMO policies; and Compcare and BCBSWi collectively underwrite or administer the POS policies. Independent licensees of the Blue Cross Blue Shield Association. ® ANTHEM is a registered trademark. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association

More Related